English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe CURE initiative aims to build on Case CCC’s collaborative nature to create a national network among U.S. cancer centers, and to catalyze innovative bench-to-bedside approaches to identifying and treating rare cancers.
Tag: rare cancers
Cancer moonshot grant funds research into reducing health disparities
Washington University School of Medicine in St. Louis has received a $17 million grant from the National Institutes of Health (NIH) to address disparities in cancer research, treatment and outcomes in underrepresented populations. The research, funded through the National Cancer Institute’s Cancer Moonshot program, will focus on African American patients with colorectal cancer and multiple myeloma, as well as patients of any race or ethnicity with cholangiocarcinoma, a rare cancer of the bile ducts.
‘Research autopsy’ helps scientists study why certain cancer therapies stop working
A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
MD Anderson and the Broad Institute have launched a translational research platform to study rare cancers. The initiative will lead to a first-of-its-kind resource for the scientific community and will help to accelerate new therapies for patients with rare tumor types.
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
MD Anderson and Innovent Biologics announce a strategic collaboration to develop anti-PD-1 therapy TYVYT® (sintilimab injection) in rare cancers
MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent’s anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.